Insulin detemir
Also known as: detemir insulin, IDet, Insulin detemir, insulin detemir rDNA origin, Levemir, NN304
Source Insulin detemir at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Insulin detemir is a long‑acting basal insulin analogue approved for subcutaneous injection in people with diabetes and used off‑label in cats. It provides steady insulin action to lower blood glucose, complementing other therapies when fasting glucose control is needed. Clinical studies show it achieves glycaemic reductions comparable to other basal insulins, with a safety profile that includes lower hypoglycaemia risk versus older NPH insulin.
Mechanism of Action
Insulin detemir is an analogue of human insulin that, after subcutaneous injection, is absorbed slowly and exerts its effect by binding to insulin receptors on target cells. This receptor activation triggers intracellular pathways that promote glucose uptake and inhibit hepatic glucose production, resulting in lowered blood glucose levels. Its formulation prolongs action compared with older basal insulins, providing a relatively flat insulin profile over 24 hours.
What the Research Shows
A 2024 network meta‑analysis of 44 randomized trials (23,699 participants) found that insulin detemir reduced HbA1c to a similar extent as other basal insulins, with no significant difference in overall glycaemic efficacy. Detemir, along with degludec and glargine, showed lower odds of overall, nocturnal, and severe hypoglycaemia compared with NPH insulin, though certainty for weight outcomes was low. In a 2023 pregnancy trial, detemir was non‑inferior to insulin degludec for maternal HbA1c before delivery, with no new safety signals. Veterinary guidelines (2015) recommend detemir as a longer‑acting option for diabetic cats, citing improved glycaemic control and potential for remission. Primary‑care guidance (2021) describes initiation at 10 U/day or 0.1–0.2 U/kg with titration based on fasting glucose, noting its suitability for basal therapy.
Reported Benefits
Clinical evidence indicates insulin detemir provides glycaemic control comparable to other basal insulins while offering a reduced risk of hypoglycaemia relative to NPH insulin. It can be used safely during pregnancy, as demonstrated by non‑inferiority to degludec in a randomized trial. In cats, detemir is listed among longer‑acting insulins that may improve control and support remission. Its once‑daily or twice‑daily dosing flexibility aids patient adherence.
Limitations of the Evidence
Weight‑gain advantages of detemir are uncertain, with low‑certainty evidence showing no clear benefit over other basal insulins. Direct head‑to‑head trials with newer analogues are limited, and most data derive from network meta‑analyses rather than individual powered studies. Pregnancy data come from a single trial, and long‑term neonatal outcomes remain under‑explored. Veterinary recommendations are based on consensus rather than robust randomized data, highlighting a need for more controlled studies.
Safety Considerations
Insulin detemir shares typical insulin‑related adverse effects, chiefly hypoglycaemia, though rates are lower than with NPH insulin. The pregnancy trial reported no additional safety concerns versus degludec. As with all insulins, dosing errors can lead to severe hypoglycaemia. In cats, careful monitoring is required to avoid hypoglycaemic episodes. No specific organ toxicity has been identified in the cited studies.
How It Is Administered
Insulin detemir is administered by subcutaneous injection, commonly as a 100 U/mL solution. Initiation in adults often starts at 10 U daily or 0.1–0.2 U/kg, with titration based on fasting glucose targets. It may be given once daily or divided twice daily, depending on individual response. Veterinary use follows similar subcutaneous routes adapted for feline dosing.
Routes of Administration
Goals & Uses
- Glycemic control during pregnancy (diabetes)Obstetric/endocrineModerate
- Weight neutrality relative to NPHMetabolicModerate
- Glycemic controlDiabetesHigh
- Basal glycemic control in type 1 diabetesGlycemic ManagementHigh
- Basal glycemic control in type 2 diabetesGlycemic ManagementHigh
- Reduction of nocturnal hypoglycemiaSafety / TolerabilityModerate
Contraindications
- Severe hypoglycemiaMetabolicHigh
- Hypersensitivity to insulin detemirAllergyHigh
- Intravenous or intramuscular administrationRoute Of AdministrationHigh
- Hypersensitivity to insulin detemir or excipientsImmunologicHigh
- Hypoglycemia (active episode)MetabolicHigh
Adverse Effects
- HypoglycemiaMetabolicCommonAbnormally low blood glucose
- Peripheral edemaFluid BalanceUncommonSwelling of the arms or legs
- Allergic reactionsImmunologicalRare
- Injection site reactionsLocalCommon
- Allergic reactions / anaphylaxisImmunologicRare
- Weight gainMetabolicCommonIncrease in body weight
- LipodystrophyDermatologicUncommon
Drug Interactions
- Thiazolidinediones (e.g., pioglitazone)Moderate
- Salicylates (high-dose)Low
- Beta‑blockersModerate
- Other antidiabetic agents (e.g., sulfonylureas, GLP‑1 agonists)High
- Beta-blockersModerate
- AlcoholModerate
- CorticosteroidsModerate
- Antidiabetic agents (oral hypoglycemics, other insulins)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairmentOrgan FunctionRelative
- Renal impairmentOrgan ImpairmentRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Elderly patientsAgeRelative
- Pediatric patients (<2 years)AgeRelative
- Pediatric patients <2 yearsAgeAbsolute
Regulatory Status
- European UnionApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusEMA approved; same indications
- United StatesApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusFDA approved; marketed as Levemir
- United KingdomApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusMHRA approved
Administered subcutaneously; not approved for oral or inhalation routes. Requires dose titration to avoid hypoglycemia.
Evidence & Sources
- Journal ArticleHighDehghani M, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleLowSparkes AH, et al.2015-01-01T00:00:00.000000Z
- Journal ArticleModerateMehta R, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateMathiesen ER, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModeratePicón-César MJ, et al.2021-01-01T00:00:00.000000Z
Frequently Asked Questions
How does insulin detemir differ from NPH insulin?
Detemir provides a more prolonged and stable insulin level over 24 hours, resulting in similar glucose‑lowering efficacy but a lower incidence of overall, nocturnal, and severe hypoglycaemia compared with NPH, according to a network meta‑analysis of randomized trials.
Can insulin detemir be used safely during pregnancy?
A 2023 randomized trial in women with type 1 diabetes showed detemir to be non‑inferior to insulin degludec for maternal HbA1c before delivery, with no new safety issues observed, supporting its safe use in pregnancy.
Is insulin detemir appropriate for diabetic cats?
Veterinary consensus guidelines list detemir as a longer‑acting insulin option for cats, noting it can improve glycaemic control and may aid remission, though evidence is based on expert opinion rather than large controlled studies.
What dosing strategy is recommended for starting detemir in adults?
Primary‑care guidance suggests beginning with 10 units per day or 0.1–0.2 units per kilogram, then titrating upward (e.g., 1 unit daily or 2–4 units weekly) based on fasting plasma glucose until targets of 80–130 mg/dL are reached.
Does insulin detemir cause weight gain?
Current comparative evidence does not show a clear advantage of detemir over other basal insulins regarding weight gain; the certainty of available data on this outcome is low.
What is Insulin detemir?
Insulin detemir is a long‑acting basal insulin analogue approved for subcutaneous injection in people with diabetes and used off‑label in cats. It provides steady insulin action to lower blood glucose, complementing other therapies when fasting glucose control is needed. Clinical studies show it achieves glycaemic reductions comparable to other basal insulins, with a safety profile that includes lower hypoglycaemia risk versus older NPH insulin.
What is Insulin detemir used for?
Insulin detemir is educationally associated with: Glycemic control during pregnancy (diabetes), Weight neutrality relative to NPH, Glycemic control, Basal glycemic control in type 1 diabetes, Basal glycemic control in type 2 diabetes, Reduction of nocturnal hypoglycemia. Educational only — not medical advice.
How is Insulin detemir administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Insulin detemir?
Reported adverse effects include: Hypoglycemia, Peripheral edema, Allergic reactions, Injection site reactions, Allergic reactions / anaphylaxis, Weight gain, Lipodystrophy. This list is not exhaustive — consult a qualified clinician.
Who should avoid Insulin detemir?
Recorded contraindications: Severe hypoglycemia, Hypersensitivity to insulin detemir, Intravenous or intramuscular administration, Hypersensitivity to insulin detemir or excipients, Hypoglycemia (active episode). Consult a qualified clinician before use.